… new available therapeutic options is of paramount importance to … In conclusion, antiangiogenic
drugs targeting the VEGF … To date, erlotinib still represents a potential option in pretreated …

… included until to now docetaxel, pemetrexed or erlotinib, that … patients approaching a
second-line therapy, it is important to define a … In conclusion, different drugs are now or will be …

… In conclusion, antiangiogenic drugs targeting the VEGF pathway have … To date, erlotinib
still represents a potential option in … These findings highlight the importance of repeat biopsies …

… Targeted therapies improve cancer outcomes and quality of … in the first-line setting, erlotinib
dominates chemotherapy in … three strategies for second-line erlotinib initiation in nonsmall…

… increased therapeutic options for patients with NSCLC in the … This paper explores the recent
findings about nivolumab for … the second-line setting: docetaxel, pemetrexed, and erlotinib. …

… the development of additional therapeutic options in first as well … Our findings clearly highlight
that, in patients progressed … after upfront erlotinib or gefitinib therapy who did not receive a …

… important to add that all the trials assessing the addition of bevacizumab to osimertinib
reported negative findings, both in second-line … the first-line therapeutic option in patients who …

… , including findings from the expert panel discussions, … significance of these findings in the
absence of therapy in … (ORR) for neoadjuvant erlotinib therapy versus chemotherapy was not …

… have played a role in the preference … experts for their drug choice and provides a quantification
of discrepancies among them. As outcomes of patients with SCLC receiving second-line …

… ) erlotinib, were approved for clinical use in the second-line … available therapeutic options
is of paramount importance to … second-line treatment choice such as the type and outcomes …